Trial Profile
A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in dementia diagnostic category and diagnostic confidence after DaTSCAN imaging in subjects with an uncertain diagnosis of dementia with Lewy bodies (possible DLB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Ioflupane 123I (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors GE Healthcare
- 02 Sep 2015 New trial record